Related Experiment Videos
Thrombus imaging with a technetium-99m-labeled activated platelet receptor-binding peptide
J Lister-James1, L C Knight, A H Maurer
1Diatide, Inc., Londonderry, New Hampshire 03053, USA.
Summary
This study evaluated 99mTc-P280, a novel peptide agent, for preclinical thrombus imaging. Results show high specificity and affinity for activated platelets, supporting its potential for clinical use.
Area of Science:
- Nuclear medicine
- Radiopharmaceutical development
- Cardiovascular imaging
Background:
- Activated platelets express GPIIb/IIIa receptors, crucial targets for thrombus imaging.
- Current imaging agents may lack specificity or have suboptimal pharmacokinetic profiles.
Purpose of the Study:
- To conduct a preclinical evaluation of 99mTc-P280, a technetium-99m-labeled peptide, as a potential thrombus imaging agent.
- To assess the affinity, specificity, and in vivo performance of 99mTc-P280.
Main Methods:
- Assessed P280 peptide affinity and specificity via inhibition of platelet aggregation and receptor binding assays.
- Radiolabeled P280 with 99mTc.
- Evaluated in vivo thrombus detection in a canine model and determined biodistribution in rats and rabbits.
Main Results:
- P280 peptide demonstrated high in vitro affinity and specificity for the GPIIb/IIIa receptor.
- 99mTc-P280 was prepared with high radiochemical purity and effectively imaged femoral vein thrombi in canines.
- Studies showed rapid blood clearance and renal excretion of 99mTc-P280.
Conclusions:
- 99mTc-P280 exhibits high in vitro receptor binding affinity and specificity.
- Successful in vivo thrombus imaging and favorable pharmacokinetic properties were demonstrated.
- These findings support the further clinical evaluation of 99mTc-P280 as a thrombus imaging agent.